젠큐릭스
Financials
Valuation Metrics
젠큐릭스's Market Cap is ₩466B. At end of 2025 it was ₩363B. Ranked #1819 of 2,421 in KR market (top 75%), #1114 of 1,640 on KOSDAQ (top 68%), #76 of 96 in Health Care Equipment & Services (top 79%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 46.62B KRW | KR#1,819/2,421 Sec#76/96 |
| Revenue | 8.93B KRW | KR#2,295/2,421 Sec#83/96 |
| Net Income | -7.51B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 31.17B KRW | KR#2,331/2,421 Sec#87/96 |
| Net Assets | 12.61B KRW | KR#2,357/2,421 Sec#93/96 |
| Employees | 68 | KR#1,905/2,421 Sec#79/96 |
| Value | ||
| P/B | 3.64x | KR#2,164/2,421 Sec#81/96 |
| P/S | 5.13x | KR#2,153/2,421 Sec#75/96 |
| FCF Yield | -13.59% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -59.55% | KR#2,298/2,421 Sec#88/96 |
| ROA | -24.08% | KR#2,274/2,421 Sec#82/96 |
| Op. Margin | -60.44% | KR#2,253/2,421 Sec#80/96 |
| Revenue Growth | 19.67% | KR#563/2,421 Sec#31/96 |
| Earnings Growth | -180.89% | KR#1,227/2,421 Sec#44/96 |
| Financial Health | ||
| Debt Ratio | 147.29% | KR#1,893/2,421 Sec#86/96 |
| Total Debt | 10.62B KRW | KR#1,605/2,421 Sec#50/96 |
| FCF | -6.34B KRW | KR#1,564/2,421 Sec#53/96 |
| Cash | 97.2M KRW | KR#2,385/2,421 Sec#96/96 |
| Current Ratio | 0.48x | KR#2,154/2,421 Sec#91/96 |
| Performance | ||
| 1Y Return | 24.84% | KR—/2,421 Sec—/96 |
| 1M Return | 9.76% | KR—/2,421 Sec—/96 |
| From 52W High | -72.81% | KR#2,256/2,421 Sec#89/96 |
| 1Y MDD | -76.15% | KR#2,212/2,421 Sec#87/96 |
| Trading | ||
| Volume | 154,457 shares | KR—/2,421 Sec—/96 |
| Trading Value | 304.1M KRW | KR—/2,421 Sec—/96 |
| Foreign Own. | 1.71% | KR#1,749/2,421 Sec#66/96 |
| Per Share | ||
| EPS | -326 KRW | KR—/2,421 Sec—/96 |
| BPS | 547 KRW | KR#2,380/2,421 Sec#94/96 |
Company Info
Genecurix, established in 2011 as a liquid biopsy-based molecular diagnostic testing technology enterprise, was listed on KOSDAQ in 2020. The company has developed innovative cancer diagnostic solutions, including Asia's first breast cancer prognosis diagnosis GeneSWell BCT, Droplex, and early diagnostic tests HEPA eDX and COLO eDX. Genecurix has acquired a stake in GinoBio to commercialize cfDNA and research CTC technology, fostering collaborations with leading companies in core technological fields. Genecurix is headquartered in Guro-gu, Seoul Metropolitan City.